[ad_1]
US President Donald Trump received a dose of an experimental antibody drug made by the giant biopharmaceutical firm Regeneron, which has a major plant in Limerick, where it employs more than 1,000 people.
The White House announced last night that President Trump had received a single 8g dose of Regeneron’s REGN-COV2 antibody cocktail, before he was transferred to Walter Reed National Military Medical Center in Maryland.
The antibody is being manufactured at its New York facility, but the company announced last month that it was creating an additional 400 jobs at its Limerick campus to allow the company to maximize capacity at its New York facility and change the way in which some of its operations work. in light of the Covid pandemic.
Regeneron said he agreed to provide a single dose, administered intravenously, to President Trump at the request of his doctor under “compassionate use” provisions.
Antibody treatment is still undergoing clinical trials among 275 patients who have Covid-19 and are being treated in non-hospital settings.
But the trials are showing very promising results. This same week, Regeneron published that the antibody drug has reduced viral levels and improved symptoms in non-hospitalized Covid-19 patients.
It also showed positive trends in reducing medical visits.
The trial is part of a much larger program, which also includes studies on treating patients in hospital and studies on preventing infections from people who have been exposed to Covid-19 patients.
Regeneron’s President and Chief Scientific Officer George D Yancopoulos said that after months of hard work they were extremely grateful to see that Regeneron’s REGN-COV2 antibody cocktail rapidly lowered viral load and associated symptoms in Covid-infected patients. 19.
They said they were highly encouraged by the robust and consistent nature of this initial data, as well as the encouraging and well-tolerated safety profile, and have begun to discuss their findings with regulatory authorities as their trials continue.
[ad_2]